TIMEPOINT, a phase 1 study combining MTL-CEBPA with pembrolizumab, supports the immunomodulatory effect of MTL-CEBPA in solid tumorsRuth Plummer, Nagy Habib, Mikael H. Sodergren et al.|Cell Reports Medicine|2025Cited by 12
ContributorsMohamad‐Gabriel Alameh, Jiehua Zhou, Virginia Arechavala‐Gomeza et al.|Elsevier eBooks|2022Cited by 0